TROG 15.03/ANZUP 16001 FASTRACK II: economic analysis shows new technique is cheaper and more effective in the Australian setting

TRIAL UPDATE: 12 August 2025 Treating inoperable kidney cancer with Stereotactic Ablative Body Radiotherapy (SABR) is both more effective and less expensive than traditional ablative therapies in Australia, according to a new economic analysis of TROG 15.03/ANZUP 16001 FASTRACK II trial data. The findings of the  economic evaluation, published

TROG 21.07 SOCRATES HCC Trial Expands Outreach

TRIAL IN FOCUS: 29 July 2025 We’ve extended the TROG 21.07 SOCRATES HCC trial recruitment period and are now seeking participants for the trial which could provide evidence for a new and more effective treatment option for patients with early-stage hepatocellular carcinoma (HCC). While curative surgical options are recommended

Major milestone for BIG 3-07/TROG 07.01 DCIS Study

TRIAL UPDATE: 29 July 2025 A large international study focusing on radiation therapy for ductal carcinoma in situ (DCIS) of the breast has reached a significant milestone, with the database locked this month, 18 years after the first trial site was opened for recruitment. The randomised phase III study

DECREASE trial into prostate cancer

Recruitment Milestone Achieved for TROG 19.06 DECREASE Trial

TRIAL UPDATE: 8 July 2025 The TROG 19.06 DECREASE trial into advanced prostate cancer has reached a significant milestone with recruitment of the final participant in late June, bringing total recruitment to 70 participants. Congratulations to trial chairs Prof Shankar Siva and Prof Arun Azad and all involved in